Discovery and development of antiangiogenetic drugs in ovarian cancer was written by Maile, Madon M.;Wong, Evelyn Y. T.;Suzin, Daphne;Birrer, Nicole E.;Penson, Richard T.. And the article was included in Anti-Angiogenesis Drug Discovery and Development in 2014.Recommanded Product: 212141-54-3 This article mentions the following:
It is more than 30 years since the seminal observations by Folkman of the development of new blood vessels (angiogenesis) in tumors. Ovarian cancer remains the most lethal gynecol. malignancy in the US, and angiogenesis is a particularly important target as VEGF levels are high, manifest as ascites and pleural effusions, and the response rates to single agent bevacizumab, a recombinant humanized monoclonal antibody directed against VEGF, are the highest (16-25%) of any reported in oncol. Antiangiogenics have generally been well tolerated, but are associated with gastrointestinal perforation in 1-2%. New angiogenesis targets are being identified (ANG-2, PDGFR, FGFR, inflammation and the microenvironment), and a plethora of new agents is in clin. development: tyrosine-kinase inhibitors (sunitinib, cediranib, pazopanib), multitargeted agents (XL-184), anti-angiopoietins (trebananib), novel antivascular approaches (VB-111 and ombrabulin). Antiangiogenic therapy appears to impact PFS, but does not impact cure. In subsets of patients, it may improve overall survival (OS), and its use remains costly and controversial. Although approved in Europe, the pathway to approval of bevacizumab for ovarian cancer in the US is currently still unclear. There is a clin. need to define the role of these drugs in ovarian cancer management and to identify robust predictive biomarkers. In the experiment, the researchers used many compounds, for example, N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3Recommanded Product: 212141-54-3).
N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Phthalazines, as an important class of bicyclic N-heterocycles, have attracted sizable attention due to their valuable biological and pharmacological activities. Both pyridazine and phthalazine give rise to very good TREPR signals in rigid media at low temperatures.Recommanded Product: 212141-54-3
Referemce:
Phthalazine – Wikipedia,
Phthalazine | C8H6N2 – PubChem